Antisense News and Research

RSS
Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics reports financial results for three months ended September 30, 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Isis Pharmaceuticals CEO's letter to shareholders

Isis Pharmaceuticals CEO's letter to shareholders

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

iCo Therapeutics announces $4,000,000 brokered private placement

iCo Therapeutics announces $4,000,000 brokered private placement

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research